How do you approach palliative RT dose selection to skeletal lesions in patients with Myeloma who are actively receiving or likely to need systemic therapy?

Multiple myeloma patients with painful bone disease often present a unique constellation of clinical characteristics, such as extensive skeletal involvement, longer life expectancies, and many prior or anticipated systemic treatments. Some key features influencing my choice of radiation dose and schedule include:

1. The clinical characteristics of the lesion: A patient with pain from an uncomplicated osseous lesion is quite different from a complicated bone lesion. Complicated bone lesions, such as those with impending fracture, prior radiation therapy, and/or neurologic compromise, require greater emphasis on the potential consequences of local recurrence. They also frequently require multidisciplinary management, such as with our surgery and ...

In patients with multiple myeloma who are actively receiving or likely to need systemic therapy, I generally favor the lowest effective radiation dose that achieves the clinical objective while minimizing marrow exposure and disruption of systemic treatment. This is particularly important in myeloma, where patients often receive multiple lines of potentially myelosuppressive therapy. For an uncomplicated painful skeletal lesion, the primary goal of RT is usually rapid symptom relief rather than radiographic eradication of disease.

What I find compelling about this study is the prospective evaluation of a 4 Gy response-adapted strategy. Rather than routinely committing every patient to a conventional palliative dose upfront, patients can rece...